BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 523.88M | 426.86M | 322.29M | 256.59M | 205.46M |
| Total Depreciation and Amortization | 91.15M | 96.43M | 99.68M | 106.36M | 105.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 286.71M | 265.95M | 223.09M | 195.42M | 194.68M |
| Change in Net Operating Assets | -201.47M | -216.40M | -230.36M | -229.50M | -225.28M |
| Cash from Operations | 700.26M | 572.84M | 414.70M | 328.86M | 280.16M |
| Capital Expenditure | -76.09M | -85.42M | -94.81M | -98.08M | -98.34M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 198.58M | 221.92M | 89.94M | 63.57M | 2.87M |
| Cash from Investing | 122.49M | 136.49M | -4.88M | -34.52M | -95.47M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -494.95M | -494.95M | -494.95M | 1.62M | 1.01M |
| Issuance of Common Stock | 42.08M | 49.28M | 56.22M | 55.78M | 55.38M |
| Repurchase of Common Stock | -66.39M | -77.56M | -76.57M | -75.20M | -74.85M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.18M | -3.22M | -3.17M | -2.33M | -2.33M |
| Cash from Financing | -522.43M | -526.45M | -518.47M | -20.13M | -20.78M |
| Foreign Exchange rate Adjustments | 1.49M | 4.83M | -1.32M | 3.55M | 3.01M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 301.81M | 187.72M | -109.97M | 277.77M | 166.92M |